The possible role of bradykinin in peripheral vascular disease in relation to the rationale of treatment with pyridinolcarbamate and the possibility of a seasonal variation in sensitivity to bradykinin (to account for the findings noted) are discussed.
tion point, and measurement of cal bloodflow by venous occlusion plethysmography before and after exercise in a temperature-controlled environment. Performance in all three tests decreased during the placebo control period, making the evaluation of treatment difficult.
During the trial a significant improvement occurred in the step test. No dose-related drug effect was shown but a cumulative drug effect could not be decisively excluded. Performance in the step test correlated with alteration of external environmental temperature. Claudication point showed some improvement but only analysis over time produced a value significantly differentfrom the combined control. Calf blood-flow increased to a small extent over treatment and time but did not exceed control values sgnificantly.
The possible role of bradykinin in peripheral vascular disease in relation to the rationale of treatment with pyridinolcarbamate and the possibility of a seasonal variation in sensitivity to bradykinin (to account for the findings noted) are discussed.
The suggestion that pyridinolcarbamate, a bradykinin antagonist, may be beneficial in the treatment of atherosclerosis presents a novel and possibly valuable therapeutic approach. Initial clinical trials of the drug were promising (Shimamoto et al., 1970) . It is widely used in Japan and South America and is being studied intensively in many parts of the world. Since the overall incidence and age of onset of atherosclerosis in Japan differs from that in Western populations (Shimamoto et al., i966a) , it was thought desirable to see whether pyridinolcarbamate would be effective in a British population. The chemical structure is 2,6-pyridine-dimethanol bis (N-methylcarbamate) (Fig. i) .
Some pharmacological properties of pyridinolcarbamate in experimental animals have been previously described (Shimamoto et al., i966b; Willoughby, Lykke, and Ryan, I969) .
Subjects and methods
Tablets containing 250 mg pyridinolcarbamate and identical placebo tablets containing lactose were supplied by the Banyu Pharmaceutical Co., Tokyo. Thirty-three men with intermittent claudication not severe enough to Received 7 August I972. justify operation were selected. Patients with severe angina, diabetes mellitus, recurrent infection, cerebrovascular disease, or peptic ulceration, and those on anticoagulants were excluded. No patient had evidence of heart failure, renal or hepatic disease. The informed consent of the patients and of their general practitioners was obtained. No drugs known to affect peripheral blood vessels or clotting mechanisms were given, but any hypotensive or lipid-lowering regimens were continued. 2x2 Walton, Craig, Prior, Waterhouse, and Skilton After a preliminary control period of 8 to I2 weeks, all patients received placebo for 4 weeks. The placebo control period was followed by 3 consecutive 8-week treatment periods, during which patients were divided into three treatment groups and received placebo, or i or 2 g pyridinolcarbamate daily in the sequence shown in Fig. 2 .
The term 'placebo treatment' distinguishes placebo given during the double-blind section of the trial, from that given in the placebo control period.
In (Whitehead, I969) . Serum lipids and lipoproteins (including ultracentrifugal analysis of the latter) were measured as previously described (Craig and Walton, 1972) .
Serum and urine levels of pyridinolcarbamate and its metabolites were measured by thin-layer chromatography using a modification of a technique described by Jackson and Moss (I969).
Results
Results from 25 of the original 33 participants were used in the final analysis. Five sets of results were discarded because of unsatisfactory blood and urine levels of pyridinolcarbamate. One patient was withdrawn because of a cardiac arrhythmia, one because of diarrhoea, and one defaulted.
Results for the step test, claudication point, and blood flow were analysed. Digital palpation of leg pulses proved an unreliable method of assessing progress and the results were not used.
Control values
The mean values during the placebo control period were less than those of the control period of all tests, and the variance ratios (control: placebo control) were significantly high (P < oo5). Therefore in subsequent analyses, treatment period values were tested against both the control period value and a combined control value, this being the mean of control and placebo control values.
Results were analysed in relation to (A) treatment and (B) time. The mean results during each control and treatment period are shown in Table 3 . The data were also analysed in terms of mean change in response, using for each patient the deviation from his own control or combined control value (see Tables 3 and 4) .
Analysis of results in relation to treatment A significant improvement in performance in the step test was apparent when mean treatment values were compared with the combined control (Table 3) . However, no dose effect could be shown, and the placebo treatment mean exceeded that for 2 g pyridinolcarbamate. Claudication point improved during the treatment periods, but not significantly. Calf blood flow did not increase beyond control values with the exception of the mean peak flow after prolonged exercise on 2 g pyridinolcarbamate, but this was not significant when compared with the combined control. There was no change in basal blood flow or in 'resting' flow 20 minutes after pro- Individual results of this analysis showed that of the 25 patients, 22 had a positive response in the step test (range + 0-2 to I9 9 kg m); i6 in claudication point (range + 05 to + 38 movements); I5 in the peak calf blood flow after prolonged exercise (range + o09 to + 4-9 ml/min/ioo ml), and I2 in the Significance levels: t P < 0-05; t P < O-OI.
group.bmj.com on January 7, 2018 -Published by http://heart.bmj.com/ Downloaded from peak flow after standard exercise (range +O I to +4-I ml/min/ioo ml). In general, subjects did not show a consistent response for all four tests.
Analysis of results in relation to time
The analysis of data in relation to treatment showed no definite dose-related effect of pyridinolcarbamate. If the compound took longer to act than the 8 weeks allowed for each treatment period, an effect, including any carryover, might be reflected in the patients' performance in the third treatment period. To investigate this possibility, the data were rearranged and analysed by chronological sequence irrespective of dose. Analysis in terms of mean response (Table 3 , Part B) showed a significant increase over both the control and combined control value for the step test alone (P < o oi) during treatment periods 2 and 3. A similar tendency was shown for claudication point and peak calf blood flow after prolonged and standard exercise, but the changes were not significant. Analysis in terms of mean deviation (Table 5) showed, in addition to an enhanced degree of significance for the step test results, that claudication point and peak calf blood flow after prolonged exercise increased significantly (P < o o5) from the combined control value in periods 2 and 3, respectively. Within broad limits all tests showed basically the same pattern over time: a decrease from control values during the first part of the trial, followed by a rise in the latter half.
Evaluation of seasonal variation effect Even if the improvement in performance during the latter months of the trial could perhaps be attributed to a cumulative drug effect, the decrease during the placebo control period still needed explanation, particularly since, for all tests, the significance of the change in response was due mainly to low values during this period. Discounting an adverse placebo reaction, ambient temperature was considered as a possible complicating variable. A mean ambient temperature for each calendar week was obtained from the records of Edgbaston Observatory, and this was compared with step test results.
Step test results were available for subgroups of patients during each calendar week, and these weekly means were plotted above the mean temperature for the corresponding week. Mean monthly step test results for all patients were also compared with mean temperature over the same four-week periods. The overall picture (Fig. 3) was of performance following temperature. When a correlation analysis was carried out on mean weekly values over the trial period (both variables in logarithms), a lag period of one week gave a correlation coefficient (r=0o587, P<o-oi) which was marginally higher than the values for lag periods of 2 to 8 weeks.
It was possible that a major temperature effect was masking a subordinate drug effect. To isolate a residual element which might correlate with drug dosage, the mean weekly performance value was subtracted from each patient's result for that specific week. The resultant values were then analysed in relation to treatment, but no residual drug effect could be demonstrated. Repeating the procedure with four-point moving averages of the weekly performance values (to allow for variation between the four subgroups on which they were based) gave a similar negative result. The residual values for each patient remained remarkably constant over the trial.
Factors influencing response
The effect of smoking habits, blood pressure, and serum cholesterol level on response were examined separately. Patients were classified into 'high' and 'low' groups for each factor on a basis similar to that used in the initial stratification, a level of 260 mg/Ioo ml being used for serum cholesterol. Results were analysed in terms of the deviation of TABLE 5 Mean change in response in relation to time Results expressed as mean deviation from control (C) or combined control (CC)
Claudication
Step test Basal
Calf blood flow (ml/minlfoo ml) Significance levels: t P < o os; t P < O-OI; P <oooI. each patient from his own control for each factor in the step test, claudication point, and peak calf blood flow after prolonged exercise. For all three tests the light smokers had a greater positive mean deviation than the heavy smokers, but the results were neither statistically significant nor clearly related to pyridinolcarbamate treatment. Neither cholesterol nor blood pressure levels had any consistent or significant effect on tests.
Effect on coronary heart disease Eleven patients had electrocardiographic and/or clinical evidence of coronary artery disease before treatment. In 5 patients with angina it was unchanged subjectively in 4 and increased in i. The electrocardiogram did not change in I0 out of iI patients, but one developed coupled ventricular ectopic beats after taking i g pyridinolcarbamate and treatment was withdrawn.
Side effects Four patients developed diarrhoea on the 2 g dose. In one the diarrhoea was associated with nausea, anorexia, epigastric discomfort, and the passage of mucus rectally, and treatment was stopped. In 2 cases it was accompanied by mild depression, and in a third by early waking.
One patient with a past history of depression, having been well during the placebo control period, became depressed on 2 g pyridinolcarbamate daily, and suicidal during the subsequent placebo treatment. The depression improved on amitriptyline and did not recur when i g pyridinolcarbamate was resumed. His results were excluded.
One patient developed haematuria and an increase in SGOT while on 2 g and was found to have a papilloma of the bladder.
Biochemical and haematological results
The haemoglobin, total and differential white count remained within normal limits during treatment, as did the serum albumin, globulin, sodium, potassium, calcium, and SGOT (with the one exception noted above).
Six patients had a raised serum uric acid and five a blood urea above 40 mg/ioo ml. These abnormal values were unchanged during the trial.
No consistent changes in total cholesterol between week o and 26 were observed between two laboratories, and values in groups I and 3 (on pyridinolcarbamate week 26) were not significantly different from those in group 2 (on placebo week 26). The flotation factor (Sf) 0-20 cholesterol in all groups was lower at week 26 than at week o, the mean difference being 30 mg/ioo ml in groups i and 3 and 26 mg/ioo ml in group 2. A small but insignificant rise in Sf 20-400 cholesterol occurred in all groups.
Assessment of subjective changes At week 28, patients were asked whether their symptoms were better, unchanged, or worse during treatment, and whether the change, if any, occurred at the beginning, middle, or end of the trial. Of the 25 final participants, i6 felt better, 8 were unchanged, and i felt worse during treatment. Of the i6 who improved subjectively, I0 felt best at the end, 2 in the middle, 3 from the midpoint of the trial onwards, and i did not answer this point. When told that three doses of drug had been tested all expressed surprise.
Blood and urine drug levels The mean blood level of pyridinolcarbamate on i g daily was 9-4 ,ug/ml, and on 2 g daily was I7'3 ,ug/ml. The mean urine level of pyridinolcarbamate and its metabolites was 56-7 ,ug/ml on i g daily, and 6i-4 jg/ml on 2 g daily.
Discussion
Assessment of effect of treatment Assessment of the efficacy of medical treatment of arteriosclerosis obliterans is notoriously difficult because patients vary in the nature and extent of spontaneous progression of their signs and symptoms. Longitudinal studies by serial arteriography have, in most instances, shown either no improvement or gradual worsening of stenotic occlusions affecting the main arteries of the legs (Silbert and Zazeela, 1958; Dawson and Raphael, I968) . Arteriography was not used in the present study because of the known risks of this procedure (Chamberlain and Gleeson, I965) .
On the other hand, evaluations of function by flow measurements, "33Xe clearance, or venous occlusion plethysmography (Bloor, I96I; Tillgren and Lund, I967; Bollinger, Simon, and Mahler, I969) In this regard, it is now established that plasma proteins permeate arterial walls, probably by a process of ultrafiltration that is influenced by blood pressure and changes in endothelial permeability. The entrapment in the intimal gel of low-density lipoproteins during the passage of plasma through the wall initiates the formation of atherosclerotic plaques (Walton, I969) . Since pyridinolcarbamate partially inhibits the permeability effects of the kinins and kinin-forming enzyme kallikrein (Lykke, Willoughby, and Kosche, I967) , it seemed possible that the compound might diminish oedema formation and reverse altered permeability where bradykinin was involved.
Further work is required to establish whether pyridinolcarbamate antagonizes the effect of bradykinin on the human microcirculation and, if so, whether the haemodynamic changes are beneficial. Intra-arterial bradykinin dilates both small and large arteries and increases reactive hyperaemia after arterial occlusion (Eriksson, I969) , while a reduction in reactive hyperaemia during pyridinolcarbamate treatment has been reported (Pratesi, I972) . Changes in osmolarity (Mellander et al., I967) and of K ions (Kjellmer, I965) are regarded as important factors in the mediation of postexercise hyperaemia, but it is thought that bradykinin may also contribute (Burch and DePasquale, I963) . Despite this, it seemed justifiable to test the response to a bradykinin antagonist by assessing postexercise hyperaemia. No significant change was found.
On the other hand, some effect was noted in tests in which the end-point was determined by discomfort due to muscle pain (step test, claudication point). Rodbard and Pragay (I968) have postulated that during a muscle contraction a metabolite is produced which diffuses into the extracellular space where a specific concentration of the metabolite in contact with pain receptors causes ischaemic pain. On this basis the results noted with pyridinolcarbamate might be ascribed to decreased production or release of metabolite (by its effect on membrane permeability) or direct antagonism of the effect of the metabolite on pain receptors. It is not known whether bradykinin itself produces muscle pain, or whether bradykinin antagonists, in this sense, behave as analgesics. By analogy, it has been suggested that the analgesic effect of aspirin may be due to an action whereby it blocks the release of an intermediary vasoactive substance produced in response to bradykinin (Piper and Vane, I969 
